126 related articles for article (PubMed ID: 30032956)
1. [MBD4 inactivation induces a new mutator phenotype in cancers].
Rodrigues M; Mobuchon L; Houy A; Derrien AC; Stern MH
Bull Cancer; 2018 Sep; 105(9):736-737. PubMed ID: 30032956
[No Abstract] [Full Text] [Related]
2. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors.
Rodrigues M; Mobuchon L; Houy A; Fiévet A; Gardrat S; Barnhill RL; Popova T; Servois V; Rampanou A; Mouton A; Dayot S; Raynal V; Galut M; Putterman M; Tick S; Cassoux N; Roman-Roman S; Bidard FC; Lantz O; Mariani P; Piperno-Neumann S; Stern MH
Nat Commun; 2018 May; 9(1):1866. PubMed ID: 29760383
[TBL] [Abstract][Full Text] [Related]
3. Evolutionary Routes in Metastatic Uveal Melanomas Depend on
Rodrigues M; Mobuchon L; Houy A; Alsafadi S; Baulande S; Mariani O; Marande B; Ait Rais K; Van der Kooij MK; Kapiteijn E; Gassama S; Gardrat S; Barnhill RL; Servois V; Dendale R; Putterman M; Tick S; Piperno-Neumann S; Cassoux N; Pierron G; Waterfall JJ; Roman-Roman S; Mariani P; Stern MH
Clin Cancer Res; 2019 Sep; 25(18):5513-5524. PubMed ID: 31227496
[TBL] [Abstract][Full Text] [Related]
4. Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab.
Johansson PA; Stark A; Palmer JM; Bigby K; Brooks K; Rolfe O; Pritchard AL; Whitehead K; Warrier S; Glasson W; Hayward NK
Immunogenetics; 2019 May; 71(5-6):433-436. PubMed ID: 30714079
[TBL] [Abstract][Full Text] [Related]
5. Germline MBD4 Mutations and Predisposition to Uveal Melanoma.
Derrien AC; Rodrigues M; Eeckhoutte A; Dayot S; Houy A; Mobuchon L; Gardrat S; Lequin D; Ballet S; Pierron G; Alsafadi S; Mariani O; El-Marjou A; Matet A; Colas C; Cassoux N; Stern MH
J Natl Cancer Inst; 2021 Jan; 113(1):80-87. PubMed ID: 32239153
[TBL] [Abstract][Full Text] [Related]
6. The newest treatments for uveal melanoma.
Luke JJ
Clin Adv Hematol Oncol; 2019 Sep; 17(9):490-493. PubMed ID: 31549969
[No Abstract] [Full Text] [Related]
7. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome.
Palles C; West HD; Chew E; Galavotti S; Flensburg C; Grolleman JE; Jansen EAM; Curley H; Chegwidden L; Arbe-Barnes EH; Lander N; Truscott R; Pagan J; Bajel A; Sherwood K; Martin L; Thomas H; Georgiou D; Fostira F; Goldberg Y; Adams DJ; van der Biezen SAM; Christie M; Clendenning M; Thomas LE; Deltas C; Dimovski AJ; Dymerska D; Lubinski J; Mahmood K; van der Post RS; Sanders M; Weitz J; Taylor JC; Turnbull C; Vreede L; van Wezel T; Whalley C; Arnedo-Pac C; Caravagna G; Cross W; Chubb D; Frangou A; Gruber AJ; Kinnersley B; Noyvert B; Church D; Graham T; Houlston R; Lopez-Bigas N; Sottoriva A; Wedge D; ; ; ; Jenkins MA; Kuiper RP; Roberts AW; Cheadle JP; Ligtenberg MJL; Hoogerbrugge N; Koelzer VH; Rivas AD; Winship IM; Ponte CR; Buchanan DD; Power DG; Green A; Tomlinson IPM; Sampson JR; Majewski IJ; de Voer RM
Am J Hum Genet; 2022 May; 109(5):953-960. PubMed ID: 35460607
[TBL] [Abstract][Full Text] [Related]
8. Germline loss-of-function variants in MBD4 are rare in Finnish patients with uveal melanoma.
Repo P; Jäntti JE; Järvinen RS; Rantala ES; Täll M; Raivio V; Kivelä TT; Turunen JA
Pigment Cell Melanoma Res; 2020 Sep; 33(5):756-762. PubMed ID: 32421892
[TBL] [Abstract][Full Text] [Related]
9. [Role of MBD4 in hypermutator phenotype and malignant transformation].
Rodrigues M; Mobuchon L; Houy A; Derrien AC; Fiévet A; Stern MH
Med Sci (Paris); 2018 Nov; 34(11):925-927. PubMed ID: 30526825
[No Abstract] [Full Text] [Related]
10. Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
Villy MC; Le Ven A; Le Mentec M; Masliah-Planchon J; Houy A; Bièche I; Vacher S; Vincent-Salomon A; Dubois d'Enghien C; Schwartz M; Piperno-Neumann S; Matet A; Malaise D; Bubien V; Lortholary A; Ait Omar A; Cavaillé M; Stoppa-Lyonnet D; Cassoux N; Stern MH; Rodrigues M; Golmard L; Colas C
J Natl Cancer Inst; 2024 Apr; 116(4):580-587. PubMed ID: 38060262
[TBL] [Abstract][Full Text] [Related]
11. [Advances in uveal melanoma].
Piperno-Neumann S; Desjardins L
Rev Prat; 2014 Jan; 64(1):83-4. PubMed ID: 24649554
[No Abstract] [Full Text] [Related]
12. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
13. Changes in immunological markers and influx of macrophages following trans-scleral thermotherapy of uveal melanoma.
Dennaoui J; Bronkhorst IH; Ly LV; de Wolff-Rouendaal D; Keunen JE; Schalij-Delfos NE; Jager MJ
Acta Ophthalmol; 2011 May; 89(3):268-73. PubMed ID: 21232082
[TBL] [Abstract][Full Text] [Related]
14. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.
Saint-Ghislain M; Derrien AC; Geoffrois L; Gastaud L; Lesimple T; Negrier S; Penel N; Kurtz JE; Le Corre Y; Dutriaux C; Gardrat S; Barnhill R; Matet A; Cassoux N; Houy A; Ramtohul T; Servois V; Mariani P; Piperno-Neumann S; Stern MH; Rodrigues M
Eur J Cancer; 2022 Sep; 173():105-112. PubMed ID: 35863105
[TBL] [Abstract][Full Text] [Related]
15. HLA Class I and II genotype in uveal melanoma: relation to occurrence and prognosis.
Maat W; Haasnoot GW; Claas FH; Schalij-Delfos NE; Schreuder GM; Jager MJ
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):3-6. PubMed ID: 16384937
[TBL] [Abstract][Full Text] [Related]
16. Immunogenetic heterogeneity of uveal melanoma.
Martinetti M; Tafi A; De Paoli F; Dugoujon JM; Belvedere MC
Cancer Detect Prev; 1988; 12(1-6):145-8. PubMed ID: 3180122
[TBL] [Abstract][Full Text] [Related]
17. The Ashton Lecture. Uveal melanoma: the past, the present and the future.
Rennie IG
Eye (Lond); 1997; 11 ( Pt 2)():255-64. PubMed ID: 9349422
[No Abstract] [Full Text] [Related]
18. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
19. Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma.
Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I
Anticancer Agents Med Chem; 2017; 17(2):190-205. PubMed ID: 27109020
[TBL] [Abstract][Full Text] [Related]
20. Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects.
Baggetto LG; Gambrelle J; Dayan G; Labialle S; Barakat S; Michaud M; Grange JD; Gayet L
Cancer Treat Rev; 2005 Aug; 31(5):361-79. PubMed ID: 15994016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
